In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Invitrogen Shows That Not All Life Science is Created Equal

Executive Summary

Invitrogen's performance in 2003 indicates some of the variables involved in determining who can weather the pinch in life sciences spending. The company's experiences indicate that some sectors of life sciences--and thus pharma and biotech R&D--are doing well even if others are not. Invitrogen's cell culture business in particular is growing 30% a year due to changes in the nature of the market, and its new fluorescent probe business, acquired earlier this year, is also doing well.

You may also be interested in...



Salvia Scores $31M To Develop Neurostimulation Therapy

The Dutch start-up will use the funds to finalize product design for a neurostimulation platform targeting chronic migraines.

Signifier Medical Addresses US Sleep Disorder Market With New Funds

Signifier Medical Technologies is ramping up commercialization of its technology solutions for patients with snoring and sleep disordered breathing conditions.

Shuren: CDRH Writing Guidance To Explain What Should Happen To All Those EUA Tests, Devices

Jeff Shuren, director of the US FDA’s device center, says the agency is working on a draft guidance document that will give industry recommendations on how it should handle products granted emergency use authorization during the COVID-19 public health emergency. The guidance will also address already-approved devices that were modified by their makers under enforcement discretion.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel